west virginia glp-1 side effect class action glp 1 gip effects gip medications long term effects Managing Side Effects of Exactech Lawsuit [2026 Update] |

Suggests meaningful reductions in hard outcomes (HF hospitalization & mortality) in HFpEF with obesity + T2D, not just symptom relief

This pain may radiate to the back and is often accompanied by nausea and vomiting

Abstract: Pastore, A., Federici, G., Bertini, E., & Piemonte, F

10.1002/jcph.1119 98 MathialaganS.CostalesC.TylaskaL.KimotoE.VildhedeA.JohnsonJ.et al (2018)

Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions